派格生物医药-B今日盘中大涨5.33%，引起了市场的广泛关注。
消息面上，该股昨日因上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，导致股价出现急跌。经历昨日重挫后，今日股价出现技术性超跌反弹。
派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。
派格生物医药-B今日盘中大涨5.33%，引起了市场的广泛关注。
消息面上，该股昨日因上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，导致股价出现急跌。经历昨日重挫后，今日股价出现技术性超跌反弹。
派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.